SULPYCO Method - A New Quantum and Integrative Approach to Depression

SULPYCO METHOD

A NEW QUANTUM AND INTEGRATIVE APPROACH TO DEPRESSION

Publisher

AKUMED doo , Zagreb, Croatia

Cover design

Sandro Dukic, croatian artist

Copyright

Dr Maja Roje Novak, 2012

www.dr-roje.com

All rights reserved,

ISBN 978-953-57016-1-3

Smashwords Edition, License Notes

This ebook is licensed for your personal enjoyment only. This ebook may not be re-sold or given away to other people. If you would like to share this book with another person, please purchase an additional copy for each recipient. If you’re reading this book and did not purchase it, or it was not purchased for your use only, then please return to Smashwords.com and purchase your own copy. Thank you for respecting the hard work of this author.

Contents

Disclaimer

Introduction

Depression: a short overwiev of common knowledge

Conventional antidepressants

Homeopathy and quantum medicine

Discovery of a SULPYCO method

Observational study

Chemical model of possible interactions of sulpiride and Coenzyme compositum

Clinical experience with the SULPYCO method

Application of SULPYCO method

Afterword

References

DISCLAIMER

All information in this book is presented only for the purpose of sharing ideas. It is not intended to be a substitute for the services of health care professionals. Neither the author nor publisher is responsible for any consequences incurred by those employing the remedies or treatments herein. Any application of the material set forth in the following pages is at the reader's discretion and is his or her sole responsibility.

1. Introduction

The use of SULPYCO for treating depression and related disorders is a simple innovative method that involves a combination of two known, but very different, medicinal drugs: dissolved parenteral sulpiride—a classical neuroleptic generic drug—and Coenzyme Compositum solution (Heel, Germany), a parenteral complex and over-the-counter homeopathic and isopathic medication. The term SULPYCO stands for SULP (sulpiride), Y (and), plus CO (coenzyme); this drug was discovered accidentally, but has benefited many. The SULPYCO trademark and the hybrid content of SULPYCO are internationally patented. This bizarre blend works so well in clinical settings that it has the potential to revolutionize antidepressant therapy. Generally, it is used as a subcutaneous injection, like insulin.

I am a neurologist; I work mainly in the field of integral neurorehabilitation.

The SULPYCO method emerged accidentally, from own clinical observation and integrated medicine rationale, but outside of my core field of work.

Herein, I present a detailed description of the SULPYCO method, in a subjective manner. I am a clinical doctor who observes patients every day in my line of work, while at the same time I try to be free of any medical ideology.

Ideological (dogmatic) medical thinking emerging from conventional education often favors only a one-dimensional attitude toward medical treatment, thereby reducing the repertoire of therapeutic possibilities. So I compared my observations to conventional medical knowledge and hopefully overcame some basic misconceptions while creating new medical quality.

Throughout the course of this book, I have revealed my medical personality, as a sincere and enthusiastic physician of integrated health orientation who is looking for authentic clinical evidence and improvements.

2. Depression: a short overview of common knowledge

Depression is a common condition characterized by a disordered and low mood. Depressed patients may feel sad, guilty, anxious, helpless, empty, hopeless, and worthless. They may also have the following problems: loss of appetite or overeating, loss of interest in activities that were once pleasurable, concentration problems, contemplating or attempting suicide, insomnia or oversleeping, loss of energy, as well as physical pain and aches of various forms.

However, depression can also be a normal reaction to a particular life crisis or to medical conditions, and it can be a side effect of some medical treatments. Depressive illness is one of the highest causes of disability in the world. According to predictions of experts, depression will be the second leading cause of disability among people of all ages by the year 2020. Currently, the percentage of major depression for people seen in primary care is between 5 and 10%. The main types of depression are as follows: major depressive disorder is when a patient is unable to perform daily activities owing to disability; dysthymia is a form of a chronic, less severe, nondisabling depression; minor depression involves minor symptoms that last for more than two weeks; psychotic depression involves delusions; postnatal depression; seasonal depression; and bipolar disorder.

Another very common disorder is anxiety disorder, which is characterized by an abnormally high degree and quality of fear and anxiety of various forms, with neurotransmitter and etiological dynamics similar to those of depressive disorders.

At present, depression is known to have connections to altered brain neurochemistry. Although no single cause of depression is recognized, several hypotheses that try to explain the biology of depression probably work in concordance.

1. Monoamine hypothesis (most popular)

The monoamine hypothesis postulates that a deficiency of certain neurotransmitters is responsible for the corresponding features of depression. Those neurotransmitters are the monoamines, namely serotonin, dopamine, and norepinephrine.

However, the available evidence does not convincingly favor this theory because some studies show that the depletion of monoamines fails to cause depression in healthy subjects. In addition, some medications can consistently benefit patients with depression and are known to operate outside the monoamine system.

Monoamine oxidase A (MAO-A), an enzyme that antagonizes monoamines, may be excessively active in depressed people. This results in a subsequent lowering of the levels of monoamines. This hypothesis was acknowledged by positron emission tomography studies that found significantly elevated activity of MAO-A in the brains of some depressed patients. However, in some depressed young individuals, lowered MAO-A activity was observed as a consequence of intense stress. Thus, the data are still contradictory.

2. Altered neuroplasticity

In chronic stress and depression, synaptic and dendritic plasticity are reduced. Fortunately, antidepressant medications can enhance neuroplasticity at both molecular and dendritic levels.

3. Genetic factors

Several studies have attempted to identify genes that might influence the development of depression and its underlying mechanism. The most popular